At a glance
- Originator Schering-Plough
- Class Antihypertensives; Antiplatelets; Vasodilators
- Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Hypertension; Thrombosis
Most Recent Events
- 18 Nov 1998 No-Development-Reported for Coronary artery restenosis in USA (Unknown route)
- 18 Nov 1998 No-Development-Reported for Hypertension in USA (Unknown route)
- 18 Nov 1998 No-Development-Reported for Thrombosis in USA (Unknown route)